Sponsor: ResMed Ltd

MAR 1 - 2005

Meridian Mask Special 510(k) Premarket Notification

510(k) SUMMARY—Meridian Mask

Submitter Name:

ResMed Ltd

Submitter Address:

97 Waterloo Road, North Ryde NSW 2113, Australia

Contact Person:

David D'Cruz, VP Regulatory & Clinical Affairs US

Phone Number:

(858) 746 2238

Fax Number:

(858) 746 2915

Date Prepared:

January 20, 2005

Device Trade Name:

ResMed Meridian Mask

Device Common

Name/

Nasal Mask

Classification Name:

Predicate Devices:

K961783 Modular Mask - cleared as part of the VPAP II ST

system

Device Description:

The Meridian Mask is a respirator mask covering the nose. It is

a patient interface accessory to CPAP and bilevel devices for

use in hospitals, clinics and at home.

Intended Use:

The Meridian Nasal Mask is intended for Single Patient multi-use by adult patients (>66lb/30Kg) prescribed continuous positive airway pressure (CPAP) or bilevel

therapy in hospitals, clinics and/or home environments.

Device Technological Characteristics and Comparison to Predicate Device(s):

The Meridian Mask is strapped to the patient's face covering the nose. It is connected via tubing to a CPAP or bi-level flow generator. Positive pressure ventilation is thus applied to the lungs in a non-invasive way. The Meridian Mask is a single patient re-use medical accessory.

The Meridian Mask is a modified version of the Modular Mask (cleared by FDA in K961783). The Meridian Mask is shown to be substantially equivalent to the Modular Mask. Both masks have the same intended use, operating principle, technological characteristics and a similar manufacturing process.

Risk Analysis and Performance Data:

The risk analysis for the modified device is provided in section 5.2.1. Performance testing derived from the risk analysis is provided (section 5.2.2) in order to demonstrate safety and effectiveness of the Meridian Mask and ensure that the design input requirements have been met.

Materials Biocompatibility:

The materials used for the mask components, which contact the skin and/or the air-path, are compliant with ISO 10993 standards. Where materials have not been cleared for use by the FDA, the ISO 10993 reports have been included, section 5.4.

Conclusion:

The results of the performance data and materials biocompatibility testing show that the mask is substantially equivalent with the unmodified predicate mask.



MAR 1 - 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

ResMed, Limited C/O Mr. David D'Cruz Vice President, Regulatory & Clinical Affairs US ResMed, Corporated 14040 Danielson Street Poway, California 92064-6857

Re: K050142

Trade/Device Name: Meridian Mask Regulation Number: 21 CFR 868.5905

Regulation Name: Noncontinuous Ventilator (IPPB)

Regulatory Class: II Product Code: BZD Dated: January 20, 2005 Received: January 24, 2005

Dear Mr. D'Cruz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Indications for Use

510(k) Number (if known): K050142

| Device Name: | Meridian Mask | | |
|--|--|---|---------------|
| ndications For Use: | | | |
| The Meridian Nasal Mask prescribed continuous po and/or home environment | sitive airway pressure (C | tient multi-use by adult patients (>66lb/30 CPAP) or bilevel therapy in hospitals, cli |)Kg) inics |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Prescription Use X (Part 21 CFR 801 Subpart I | AND/OR | Over-The-Counter Use (21 CFR 807 Subpart C) | |
| (PLEASE DO NOT WE | RITE BELOW THIS LINE-CO | ONTINUE ON ANOTHER PAGE IF NEEDED) | |
| Cor | ncurrence of CDRH, Office of | f Device Evaluation (ODE) | |
| | | | |
| augne | ion_ | Page 1 of | |
| Corregen C (cn-Of) Theilisch of A nas the Collegion Coatrol, D | ciplogy, General Hospital, tental Devices | | |
| 10%) Numberk | (050142 | | |